Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart in Children With Moderately to Severely Active Ulcerative Colitis
NCT07158242Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2026
- Primary completion
- Mar 2030
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of afimkibart in ulcerative colitis (UC), sponsored by Roche. Started Apr 2026; status: recruiting.
02
Drugs
afimkibart
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07158242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07158242.